Accelemed Research Institute

Austin, Texas 78745

0 studies enrolling now · 6 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Diabetes Mellitus, Type 2, Enteric Hyperoxaluria, NASH - Nonalcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease

Studies at this site

• A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — Running, not enrolling
• Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus — Completed
• Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease — Running, not enrolling
• ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) — Completed
• Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) — Completed
• Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria — Stopped early